Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

From Denials to Decisions: Dr. Wael Khouli of Authsnap on AI-Powered Healthcare Appeals 

Shots:  Did you know that nearly 15–20% of healthcare claims in the U.S. are denied on first submission, creating billions of dollars in administrative costs and forcing providers into complex, time-consuming appeals processes that strain revenue cycles, clinical staff, and patient care continuity?    Authsnap is an AI healthcare technology company helps providers manage insurance denials and…
4 days ago

Read more

MAGAZINE

PharmaShots Magazine-March-2026 Edition

Shots AI is transforming clinical trial oversight from periodic monitoring to continuous, real-time intelligence, enabling early detection of safety signals, protocol deviations, and operational risks while strengthening data integrity and patient protection. Advanced analytics and machine learning are powering predictive, risk-based monitoring, integrating data from decentralized trials, wearables, ePROs, and multiple clinical systems to prioritize…
March 12, 2026

Read more

EVENTS

ISPE Singapore Conference & Exhibition 2026 | August 19-21 | Suntec Singapore

The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected events for bio & pharmaceutical manufacturing professionals. The annual meeting highlights best practices and services – from manufacturing facility design to finished product. Whether joining onsite in Singapore or on-demand, this is your opportunity to gather the latest updates and…
March 11, 2026

Read more

VIEWPOINTS

Bridging Innovation and Clinical Reality: Shalabh Gupta, CEO of Unicycive Therapeutics, on the Future of Biotech

Shots  Cross-industry lessons from technology, design thinking, and startups can reshape drug development by encouraging faster iteration, disciplined decision-making, and a stronger focus on real patient needs, unlocking innovations that traditional biotech models may overlook.    Clinical experience and thoughtful engagement with the U.S. Food and Drug Administration highlight the importance of patient insights, transparent…
March 9, 2026

Read more

VIEWPOINTS

Vueway Expands Pediatric Use: Alberto Spinazzi Shares Bracco Group’s Vision 

Shots:  The EU approval of Vueway for neonates, infants, and toddlers is a milestone for pediatric imaging as it allows high-quality MRI imaging at half the GBCA dose, supporting reduced gadolinium exposure in vulnerable young patients  Vueway’s gadopiclenol demonstrates safety and diagnostic performance by offering high stability, low dissociation risk, and 2.5–4× greater relaxivity than other macrocyclic GBCAs, enabling effective imaging…
March 2, 2026

Read more

TOP 20

Top 20 Radiopharmaceutical Companies of 2026

Shots:  The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care.  Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo,…
February 27, 2026

Read more

VIEWPOINTS

A New Era in Neuropsychiatry: Dr. Velichka Valcheva on GH Research’s Rapid-Acting Breakthrough, GH001

Shots:   GH001, an inhaled formulation of mebufotenin, is emerging as a highly differentiated therapy for treatment-resistant depression, delivering ultra-rapid and profound symptom improvement – patients come to the clinic depressed and many leave in remission already on the same day. Long term, in a Phase 2b trial, 73% of patients who completed six months were in remission—substantially higher than the…
February 23, 2026

Read more

VIEWPOINTS

Powering the Next Era of Animal Health: Gary Yang on CPBIO’s Global Strategy 

Shots:  CPBIO’s expanding global footprint is powered by a science-led strategy that connects innovation, partnerships, and emerging market growth with a core goal: turning evidence-based R&D into practical solutions that improve livestock productivity, resilience, and sustainability.  The company delivers species-specific solutions across poultry, swine, ruminants, and aquaculture while following a unified R&D philosophy focused on…
February 16, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in January 2026 

Shots:  Approval numbers were lower, but the impact remained strong the FDA cleared one new drug in January 2026 versus three in January 2025, reflecting continued innovation in areas of high unmet need  Zycubo from Sentynl Therapeutics was approved for pediatric Menkes disease, offering a targeted treatment for this rare, life-threatening genetic copper deficiency disorder  Clinical results were striking, showing…
February 10, 2026

Read more

INSIGHTS+

Key Biosimilars Events of January 2026   

Shots:  Global biosimilar activity accelerated across ophthalmology, oncology, immunology, and diabetes, with new or advancing alternatives to Lucentis, Eylea, Stelara, Lantus, Avastin, Opdivo, and Neulasta, expanding patient access across Europe, the US, India, Canada, Ghana, and MENA  Regulatory and commercialization momentum remained strong, marked by FDA, EC, Health Canada, and Ghana FDA milestones, alongside Samsung Bioepis’…
February 3, 2026

Read more

Load more